Thursday, February 28, 2013

Computer-Assisted Guidance for Dental Office Tobacco-Cessation Counseling: A Randomized Controlled Trial



Decreases in smoking prevalence from recent decades have slowed, and national goals to reduce tobacco use remain unmet. Healthcare providers, including those in physician and dental teams, have access to evidence-based guidelines to help patients quit smoking. Translation of those guidelines into practice, however, remains low. Approaches that involve screening for drug use, brief intervention, and referral to treatment (SBIRT) are a promising, practical solution.


This study examined whether dentists and dental hygienists would assess interest in quitting, deliver a brief tobacco intervention, and refer to a tobacco quitline more frequently as reported by patients if given computer-assisted guidance in an electronic patient record versus a control group providing usual care.


A blocked, group-randomized trial was conducted from November 2010 to April 2011. Randomization was conducted at the clinic level. Patients nested within clinics represented the lowest-level unit of observation.


Participants were patients in HealthPartners dental clinics.


Intervention clinics were given a computer-assisted tool that suggested scripts for patient discussions. Usual care clinics provided care without the tool.

Main outcome measures

Primary outcomes were post-appointment patient reports of the provider assessing interest in quitting, delivering a brief intervention, and referring them to a quitline.


Patient telephone surveys (72% response rate) indicated that providers assessed interest in quitting (control 70% vs intervention 87%, p=0.0006); discussed specific strategies for quitting (control 26% vs intervention 47%, p=0.003); and referred the patient to a tobacco quitline (control 17% vs intervention 37%, p=0.007) more frequently with the support of a computer-assisted tool integrated into the electronic health record.


Clinical decision support embedded in electronic health records can effectively help providers deliver tobacco interventions. These results build on evidence in medical settings supporting this approach to improve provider-delivered tobacco cessation.

Wednesday, February 27, 2013

Imaging Sciences International Debuts New i-CAT® FLX

New cone beam 3D system optimizes clinical control, ease of use and fast workflow.

Hatfield, PA (February 20, 2013) Imaging Sciences International is pleased to announce a new addition to the award-winning i-CAT® family of cone beam 3D imaging — the i-CAT® FLX— an innovative 3D imaging solution that can help clinicians to quickly diagnose complex problems with less radiation* and develop treatment plans more easily and accurately. This newest system to the i-CAT brand offers 3D planning and treatment tools for implants and restorations, oral and maxillofacial surgery, orthodontics, plus TMD and airway disorders.
i-CAT® FLX has a range of innovative features that deliver greater clarity, ease-of-use, and control.
  • Visual iQuityTM image technology provides i-CAT’s clearest 3D and 2D images*.
  • QuickScan+ allows for a full-dentition 3D scan at a lower dose than a panoramic image*.
  • SmartScan STUDIO’s touchscreen interface and integrated acquisition system yields more control and workflow flexibility by allowing the clinician to easily select the appropriate scan for each patient at the lowest acceptable radiation dose.
  • Ergonomic Stability System (ESS) offers seated positioning, robust head stability, and adjustable seating controls to minimize patient movement, thus reducing the need for retakes. ESS also provides wheelchair accessibility.
  • i-Collimator electronically adjusts the field-of-view to limit radiation only to the area of scanning interest.
  • i-CAT FLX’s small footprint fits easily into any practice.
  • i-PAN for traditional 2D panoramic images
    Of course, as with all i-CAT products, the Tx STUDIOTM optimized treatment planning software provides immediate access to integrated treatment tools for implant planning, surgical guides, and other applications.
    “We are thrilled to debut the i-CAT FLX — a complete 3D treatment solution,” says Kalpana Singh,
    Sr. Product Manager for Imaging Sciences International. “Given
    its high level of control over radiation dose and easy workflow, we know that the i-CAT FLX can benefit dental team members and patients they treat.”
    In 2012, Imaging Sciences International celebrated two decades of dedication to dental imaging, developing and manufacturing advanced dental and maxillofacial radiography products including the i-CAT® Next GenerationTM and i-CAT® PreciseTM and their exclusive software applications. The i-CAT brand has become among the most trusted 3D radiographic systems in the dental industry. Now, i-CAT FLX continues this legacy.

Tuesday, February 26, 2013

Carestream Health for sale, may fetch $3.5 billion - sources

Thought many of you Practiceworks, Softdent users  might be interested in this. Not sure how it could effect the company.MJ

(Reuters) - Carestream Health Inc, which provides medical imaging systems and other healthcare technology solutions, is looking for a buyer in a deal that could fetch as much as $3.5 billion, people familiar with the matter said on Monday.
Carestream, which was acquired by private equity firm Onex Corp for $2.35 billion in 2007, has hired Goldman Sachs Group, Bank of America Merrill Lynch and Credit Suisse Group to run a sale process, the people said.
The Rochester, New York-based company was formed in 2007 when the Canadian buyout firm bought Eastman Kodak Company's health group and renamed the business Carestream. The company provides digital X-ray systems, molecular imaging systems and dental imaging products, software and services.
The auction of Carestream, which is in early stages, has drawn initial interest from several large private equity firms, the people said, adding that industry buyers are less likely to participate given the company's low to negative growth.
First-round offers are due this week, one of the people added.
Carestream has around $450 million in annual earnings before interest, tax, depreciation and amortization (EBITDA) and could be sold for 7 to 8 times EBITDA, two of the people said.
All the people asked not to be named because the auction is not public. A Carestream spokesman said the company does not comment on rumor or speculation. Onex could not be immediately reached for comment, while Goldman Sachs, Bank of America and Credit Suisse declined to comment.
(Reporting by Soyoung Kim in New York; Editing by Gary Hill and Tim Dobbyn)

Join me at the Dentistry Show on Friday

I have the distinct pleasure of lecturing at The Dentistry Show in Birmingham UK on Friday March 1.

I will be doing 2 programs one on
State of the Art Diagnostics and Virtual Digital Exam in the morning
along with 2 Diode Laser programs  in the afternoon.

So if you are in the UK and cane make it I would love for you to come by and say hello. 

Monday, February 25, 2013

A little more on DentrixAscend- cloud Based Practice Managment

I am getting a lot of questions about DentrixAscend so check out the video and web site 

to learn more about this cloud based practice management system.

It is beta at this time but you can sign up to be considered for the beta. Look for full release later in the year.

Sunday, February 24, 2013

The influence of prophylactic antibiotic administration on post-operative morbidity in dental implant surgery. A prospective double blind randomized controlled clinical trial

Nolan R, Kemmoona M, Polyzois I, Claffey N. The influence of prophylactic antibiotic administration on post-operative morbidity in dental implant surgery. A prospective double blind randomized controlled clinical trial. Clin. Oral Impl. Res. 00, 2013; 18.



A prospective double-blind randomised controlled trial was conducted to test the effect of prophylactic antibiotics on post-operative morbidity and osseointegration of dental implants.

Materials and Methods

Fifty-five subjects scheduled for implant surgery were enrolled. The patients were randomly assigned to the antibiotic (test group) and placebo (control group). Twenty-seven patients (test group) received 3 g amoxicillin one hour pre-operatively, and 28 patients (control group) received placebo capsules 1 h pre-operatively. No post-operative antibiotics were prescribed. Pain diaries and interference with daily activities diaries were kept by the patients for 1 week post-operatively. Signs of post-operative morbidity (swelling, bruising, suppuration and wound dehiscence) were recorded by the principal investigators at day 2 and day 7 following the operation. Osseointegration was assessed at 2nd stage surgery or 3–4 months post-operatively.


The results of this study suggest that the use of prophylactic pre-operative antibiotics may result in higher dental implant survival rates (100% vs. 82%). Five implant failures, one in each of five patients, were reported in the placebo group and none in the antibiotic group (= 0.0515). No significant differences were found for most of the signs of post-operative morbidity 2 and 7 days post-operatively. Only bruising at 2 days following the operation appeared to be higher in the placebo group (= 0.0511). Post-operative pain (= 0.01) and interference with daily activities (= 0.01) appeared to be significantly lower for the antibiotic group after 7 days. Those patients with implant failure reported higher pain (based on the VAS scores) after 2 days (= 0.003) and after 7 days (= 0.0005), higher pain (based on the amount of analgesics used) after 7 days (= 0.001) and higher interference with daily activities (based on the VAS scores) after 2 days (= 0.005).


The use of for dental implant surgery may be justified, as it appears to improve implant survival in the short term and also results in less post-operative pain and interference with daily activities. From the results of this study, it appears that prophylactic antibiotics may also be beneficial both in terms of implant survival, especially when the surgical procedure is prolonged due to its difficulty, high number of implants placed or operator's inexperience.

Saturday, February 23, 2013

Effect of ceramic shade on the degree of conversion of a dual-cure resin cement analyzed by FTIR

Dental Materials
Volume 29, Issue 3 , Pages 317-323, March 2013



The aim of this research was to evaluate the degree of monomer conversion of different resin cement shades when photocured under different feldspathic ceramic shades. The photocuring time was also evaluated as well as the translucency of each ceramic shade.


Three VITA VM7 ceramic shades (Base Dentin 0M1, Base Dentin 2M2 and Base Dentin 5M3) were used to determine the translucency percentage. A spectrophotometer MiniScan was used to measure the opacity percentage of each specimen (2-mm-thick) and then the translucency was calculated. To measure the degree of conversion (DC), the resin cement (Variolink II; A3 Yellow and transparent) specimens (thickness: 100μm) were photocured under a ceramic block (2-mm-thick) for 20 or 40s. Specimens photocured without the ceramic block were used as control. Sixteen groups (n=3) were evaluated. Micro-ATR/FTIR spectrometry was used to evaluate the extent of polymerization of all specimens after 24h. The %DC was calculated of experimentally polymerized versus maximally polymerized composite.


The translucency percentages of 0M1, 2M2 and 5M3 ceramics were 12.41 (1.02)%, 5.75 (1.91)% and 1.07 (0.03)%, respectively. The %DC of both resin cement shades cured under ceramic 5M3 was significantly lower than the other groups (p<0.05). The %DC of 0M1 groups exhibited no significant difference from 2M2 groups (p>0.05), with the exception of the transparent cement photocured for 40s.


Photocuring under 2mm ceramic showed that the increase in chroma saturation significantly decreased Variolink II resin cement %DC (100-μm-thick).

Friday, February 22, 2013

Incorporation of antimicrobial agents can be used to enhance the antibacterial effect of endodontic sealers

Dental Materials
Volume 29, Issue 3 , Pages e29-e34, March 2013



The antibacterial activity of five endodontic sealers against three different microorganism strains alone and following incorporation of 2% benzalkonium chloride (BC) and 2% cetylpyridinium chloride (CPC) was evaluated.


The agar diffusion method was used to determine the inhibitory effect of the following endodontic sealers: RoekoSeal, Endomethasone N, N2, Apexit Plus and AH plus, on Streptococcus mutans – ATCC 25175, Lactobacillus casei – ATCC 4646 and Actinomyces viscosus – ATCC 19246. Bacterial strains were inoculated into BHIB, and incubated in an anaerobic atmosphere (37°C). From the bacteria grown in the liquid medium, the density of the inoculum was set to be equivalent to McFarland 2 standard. In Shaedler agar, 350μL of the bacterial suspension were equally spread. Specimens (4mm×6mm) were prepared from each material without and with addition of 2% BC or 2% CPC. The inhibition zones were determined after 2 days, after 7 days and after 21 days of incubation.


The largest inhibition zones were shown at zero time in all cases, with progressively less inhibition at 7 and 21 days. Endomethasone N and N2 showed the most intense antimicrobial activity, while RoekoSeal showed the least antimicrobial effect. The most susceptible microorganism was A. viscosus. Greater antimicrobial effects were found following incorporation of BC or CPC, and generally, BC gave greater inhibition zones than CPC.


Adding either BC or CPC has the potential to improve clinical outcomes with endodontic sealers, as these substances enhance the short-term antimicrobial effects of the sealers.

Thursday, February 21, 2013

Henry Schein Introduces Cloud-Based Dentrix® Ascend

Beta Version of New Practice Management System for Single and Multi-site Dental Practices Unveiled at Chicago Midwinter Dental Meeting

MELVILLE, N.Y., Feb. 21, 2013 /PRNewswire/ -- Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners, today introduced the beta version of Dentrix® Ascend, its first cloud-based practice management system designed with advanced features for single and multi-site dental practices.

With final release expected later this year, the Dentrix Ascend beta provides dentists with an early view of how the new system streamlines daily operations, blends electronic services directly into practice workflow, and takes advantage of today's advanced cloud technology. With Dentrix Ascend, dentists can safely store practice data in the cloud, manage multi-site practices and access information about their practice anytime, anywhere. Dentists who practice in multiple sites can access a single database from any location to create reports, track patient care and centralize business operations.

Dentrix® Ascend can be used on a PC or a Mac through the Google Chrome browser. It is also optimized for Safari on the Apple iPad. In addition, subscriptions for the Dentrix Ascend service will be offered on a month-to-month basis, offering dentists greater flexibility than long-term service contracts. The new system also includes many features that are typically add-on modules for a single monthly price.

"This is a completely re-imagined practice management system," said Kevin Bunker, President, Henry Schein North America Dental Practice Solutions. "We combined the best ideas from our current, highly acclaimed Dentrix system, with more than two years of research with dentists, to develop an entirely new system that improves practice management

Dentrix Ascend includes a unique approach to managing office workflow that delivers real-time information and suggested tasks specific to each user's role in the practice, prioritizes these tasks based on the dentist's efficiency and operational goals, and ultimately guides each user through a process for successfully accomplishing these tasks.

"Dentrix Ascend is the answer I have been looking for," said Jeff Burg of Burg Pediatric Dentistry in Sandy, Utah, and a beta tester for the past three months. "The new system makes operating multiple sites super easy, and I am confident that with Dentrix and Henry Schein my new web-based practice management system is in the most reliable hands."

For more than a decade, Henry Schein has delivered electronic services for Dentrix users in the cloud, using its server farms located throughout the United States. "We will deliver the same Henry Schein guarantee of quality service for Dentrix Ascend as we do for customers of our current Dentrix system and its eServices," Mr. Bunker added.

Henry Schein is committed to providing dentists with choices for a practice management solution that best fits their practice needs, whether that is Windows, Mac or the cloud. In addition to Dentrix Ascend, Henry Schein is strongly supporting and expanding its original Windows-based Dentrix system. Last year, Henry Schein released Dentrix G5 and the Dentrix Developer Program, as well as Dentrix Marketplace, which offers developers the ability to create and sell integrated applications for the Dentrix system.

As part of the Dentrix Ascend beta launch, Henry Schein also announced the Early Adopter Program to recruit qualified practices to provide user input during development at a discounted subscription price. Early feedback from beta testers has been extremely positive.

For more information, visit the Dentrix Ascend Web site at

About Henry Schein, Inc.

Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, medical and animal health practitioners. The Company also serves dental laboratories, government and institutional health care clinics, and other alternate care sites. A Fortune 500® Company and a member of the NASDAQ 100® Index, Henry Schein employs more than 15,000 Team Schein Members and serves more than 775,000 customers.

The Company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of more than 96,000 branded products and Henry Schein private-brand products in stock, as well as more than 110,000 additional products available as special-order items. The Company also offers its customers exclusive, innovative technology solutions, including practice management software and e-commerce solutions, as well as a broad range of financial services.

Headquartered in Melville, N.Y., Henry Schein has operations or affiliates in 25 countries. The Company's sales reached a record $8.9 billion in 2012, and have grown at a compound annual rate of 17 percent since Henry Schein became a public company in 1995. For more information, visit the Henry Schein Web site at

Cautionary Note Regarding Forward-Looking Statements

In accordance with the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

These statements are identified by the use of such terms as "may," "could," "expect," "intend," "believe," "plan," "estimate," "forecast," "project," "anticipate" or other comparable terms. A full discussion of our operations and financial condition, including factors that may affect our business and future prospects, is contained in documents we have filed with the SEC and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: effects of a highly competitive market; our dependence on third parties for the manufacture and supply of our products; our dependence upon sales personnel, customers, suppliers and manufacturers; our dependence on our senior management; fluctuations in quarterly earnings; risks from expansion of customer purchasing power and multi-tiered costing structures; possible increases in the cost of shipping our products or other service issues with our third-party shippers; general global macro-economic conditions; disruptions in financial markets; possible volatility of the market price of our common stock; changes in the health care industry; implementation of health care laws; failure to comply with regulatory requirements and data privacy laws; risks associated with our global operations; transitional challenges associated with acquisitions and joint ventures, including the failure to achieve anticipated synergies; financial risks associated with acquisitions and joint ventures; litigation risks; the dependence on our continued product development, technical support and successful marketing in the technology segment; risks from rapid technological change; risks from disruption to our information systems; certain provisions in our governing documents that may discourage third-party acquisitions of us; and changes in tax legislation. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

Wednesday, February 20, 2013

Henry Schein launches new cloud-based practice management system

It’s official. I just learned Henry Schein, the makers of Dentrix and Easy Dental, is launching a new cloud-based practice management system at Chicago MidWinter Meeting. I was lucky to get a demo of the system this Summer at the Dentrix Summit and I was quite impressed with the interface and ease of use. 
This is not just a port of Dentrix to the cloud. It is a completely new system. Henry Schein developers spent two years in research and development working with dentists to design a new interface and workflow from the ground up. It is designed to deliver information and prioritized tasks to each team member based on their role in the office. So screens will be different for the front desk compared to hygiene. The most used screens will by the appropriate staff member will be easily available to them.

On Thursday, Henry Schein will unveil the beta version in booth 2516 at the Chicago meeting and will be accepting applications for beta testers.  They say the final version will be released by the end of the year. So if you are interested in beta testing be sure to contact Dentrix.

I cannot tell you the product name yet because that is a surprise for on Thursday at the formal announcement, but it is safe to say it will have Dentrix in the name, even though it does not look like the Dentrix many of you know.
Keep your eyes on the blog for the latest information on this new cloud based practice management software. 

Tuesday, February 19, 2013

Charles Whitney, MD Says Dentistry Will Play a Major Role in the“Third Era of Medicine” to Help Reverse the Declining Health of The American Public

Third Era Medicine is Focused on Creating and Restoring Health Rather Than Diagnosing and Treating Preventable Conditions

Washington Crossing, PA – February 13, 2013 – Charles (Chip) Whitney, MD owner of Revolutionary Health Services in Washington Crossing, is one of the nation's leading advocates and educators regarding the Third Era of Medicine, which represents a major change in the mindset of physicians, where the focus is to empower motivated patients to create health. At its core, a Third Era Practice attempts to bridge the gap between standard of care and optimal care by using underutilized innovative technologies and methods supported by institutions like the Cleveland Clinic and the American Heart Association.

Dr. Whitney is vice president of the American Academy of Private Physicians (, a growing group of medical doctors, also historically known as concierge medicine or direct primary care practitioners. Dr. Whitney has been actively introducing Third Era principles to local residents and allied health professionals such as dentists and hygienists since 2003.

Dr. Whitney strongly recognizes that poor oral health can strongly impact a patient's overall health and has become one of dentistry’s biggest physician allies. Here are some examples:

• Partnered with key opinion leader Richard Nagelberg, DDS, to introduce their respective patients to the Carotid Intima-Media Thickness (CIMT) Ultrasound. CIMT is a non-invasive, state-of-the-art test that can detect plaque earlier in its development than any other cardiovascular screening test available.

• Authored a “Viewpoint” guest editorial in Dentistry Today, criticizing the confusing message issued by The American Heart Association regarding whether or not there is enough evidence to support the link between periodontal disease and heart disease.

• Is an active member of the American Academy of Oral Systemic Health which is a strong proponent of Physician-Dentist collaboration to treat the entire patient in order to achieve optimal overall health.

• Uses the MyPerioPath® salivary diagnostic test from OralDNA Labs on patients to detect whether high risk oral bacteria are a contributor to his patients’ vascular disease.

• When appropriate, refers sleep apnea patients to qualified dentists for a custom-fitted oral appliance in order to control their sleep disordered breathing

• Authored the 4-part continuing education course for dental professionals entitled “A Comprehensive Review of Vascular Disease,” which is posted on The purpose of the course is to help dental professionals understand their critical role in treating and preventing the cause of heart attacks and strokes. Dentists, hygienists, and dental assistants can earn up to 8 credits by completing the courses.

According to Dr. Whitney, “All humans are ‘rusting’ — that is the degenerative mechanisms that lead to disease are fully in motion, yet the individual does not yet feel it. People who are objectively shown the progression of their “rust” are intrinsically motivated to make the focused changes needed to improve their health path.

Heart attacks can be life-threatening. Dr. Whitney has seen many patients whose oral inflammation caused by high risk bacteria is a major contributor to their cardiovascular disease. With proper home treatment and intervention by their dentist and hygienist, he has seen risk factors dramatically improve, and even seen the reverse of objective disease. “In my opinion, of all allied health practitioners, dentists and hygienists may ultimately be shown to play the biggest supporting role in combating and preventing systemic disease. For the sake of our patients, we need to close the loop on medicine and dentistry.”

To learn more about the Third Era of Medicine, direct primary care and private physicians, download the free article entitled “The Third Era of Medicine: A Functional Approach to restoring the Health of America,” from You can also contact Dr. Whitney at 215-321-1371.

About Dr. Charles (Chip) Whitney and Revolutionary Health Services:

Dr. Charles Whitney graduated from Jefferson Medical College in Philadelphia in 1990 and completed his family practice residency at the David Grant United States Air Force Medical Center. He is double Board Certified in the specialties of Family Medicine and Sports Medicine. His experience includes seven years as an Air Force physician and seven years in the University of Pennsylvania Health System before establishing his own “concierge” practice, Revolutionary Health Services in 2003.
 For more information, visit

1121 General Washington Memorial Boulevard, Washington Crossing, Pa. 18977 Tel: 215-321-1371 Fax: 215-321-1378

Monday, February 18, 2013


CERRITOS, Calif. (February 14, 2013) Millennium Dental Technologies Inc. (MDT) is pleased to announce the completion of initial LANAP® protocol clinical training and licensure by two internationally known periodontal disease researchers and clinicians at Temple University in Philadelphia. 
Thomas E. Rams, DDS, MHS, and Jon B. Suzuki, DDS, PhD, MBA, are board-certified periodontists, both holding appointments as Professors in the Department of Periodontology and Oral Implantology at Temple University School of Dentistry, and in the Department of Microbiology and Immunology at Temple University School of Medicine. 
“Millennium Dental Technologies has built its growing reputation in the dental profession on providing outstanding quality lasers, comprehensive and supportive LANAP protocol training for dentists, and a commitment to ongoing scientific research” says Dr. Rams. “The company has done an impressive job of developing new technologies and clinical procedures to effectively treat periodontal disease and save natural teeth for potentially millions of patients.”
Dr. Rams holds the Paul H. Keyes Professorship in Periodontology at Temple University, is the Pennsylvania Health Department-licensed Director of the dental school’s Oral Microbiology Testing Service Laboratory, and is noted for his published research on periodontal and peri-implant microbiology, and microbiologically modulated anti-infective periodontal therapy.
Dr. Suzuki serves as Chairman of the dental school’s Department of Periodontology and Oral Implantology, and as Director of its graduate periodontology specialty training program.  Dr. Suzuki is past Dean of the University of Pittsburgh School of Dental Medicine, current President of the International Congress of Oral Implantologists, and is considered a world-authority on periodontal immunology and aggressive forms of periodontitis.
“We are proud to count esteemed researchers and clinicians Drs. Rams and Suzuki among LANAP protocol-trained clinicians.  They both exemplify and extend our company’s commitment to the science supporting the LANAP treatment,” said Robert H. Gregg, DDS, President and Co-Founder of Millennium Dental Technologies.
Drs. Rams and Suzuki are planning to conduct independent laboratory and clinical studies focusing on the antimicrobial effects of MDT’s PerioLase® MVP-7™ Digital TruePulse™ Nd:YAG laser as it is employed in the FDA-cleared LANAP periodontal treatment protocol, which is regarded as a potentially revolutionary and patient friendly form of regenerative periodontal therapy. “We aim to assess dental plaque microbial changes on teeth that are treated with the LANAP protocol  to see how much this accounts for the extraordinary improvements that have been observed in many patients successfully treated with this approach, “explains Dr. Rams.  
These research activities are to be supported by funds from the Paul H. Keyes Professorship in Periodontology held by Dr. Rams, which also facilitated Temple University’s acquisition of a PerioLase MVP-7 Digital TruePulse Nd:YAG laser, and LANAP clinical training/licensure for Drs. Rams and Suzuki.
ABOUT MILLENNIUM DENTAL TECHNOLOGIES, INC. Headquartered in Cerritos, Calif., Millennium Dental Technologies, Inc. is the developer of the LANAP® protocol for the treatment of gum disease and the manufacturer of the PerioLase® MVP-7 digital dental laser. By providing a less destructive and more tissue-sparing experience with unique bone-building clinical results, MDT’s FDA-cleared LANAP protocol removes the fear from gum disease treatment, offering a vastly less painful and less invasive regenerative treatment alternative to conventional scalpel/suture flap surgery. The PerioLase® MVP-7 is a 6-watt free-running variable pulsed Nd:YAG dental laser featuring digital technology and 7 pulse durations—the most available on the market—giving it the power and versatility to perform a wide range of soft- and hard-tissue laser procedures and the only laser properly configured to support the LANAP protocol for all periodontal case types. Established in 1990, the company’s founding clinicians, Robert H. Gregg, II, DDS, and Delwin K. McCarthy, DDS, continue to operate the company with a shared vision and purpose: To create better clinical outcomes in patients with periodontal disease—and to remain true to the guiding principle—“It’s all about the patient.” For more information, visit

Saturday, February 16, 2013

Differences in peri-implant conditions between fully and partially edentulous subjects: a systematic review.

J Clin Periodontol. 2013 Mar;40(3):266-86. doi: 10.1111/jcpe.12013.



The aim of this study was to compare peri-implant conditions between fully edentulous (FES) and partially edentulous subjects (PES).


A systematic review was conducted. The MEDLINE, EMBASE and COCHRANE databases were searched for publications up to January 1st 2012. Studies reporting on the bleeding tendency of the peri-implant mucosa and/or studies reporting on the prevalence of peri-implant mucositis and/or peri-implantitis were considered.


Fifty-five publications describing 46 studies were selected. One study described both FES and PES, and all other studies described either FES or PES. Subgroup analyses were performed according to dental status (fully/partially edentulous), follow-up time (≥5 years and ≥ 10 years) and study design (prospective/cross-sectional). FES harboured more plaque at their implants than PES. Modified bleeding index scores were significantly higher in FES, but no differences in bleeding on probing, implant loss and probing pocket depth were observed between FES and PES. No meta-analysis could be performed on prevalence of peri-implant mucositis and peri-implantitis. Overall prevalence of peri-implantitis was 0-3.4% after 5 years and 5.8-16.9% after 10 years of implant evaluation.


FES and PES show comparable implant survival rates. However, no conclusion can be drawn regarding differences in prevalence of peri-implant mucositis and peri-implantitis between FES and PES.

Friday, February 15, 2013

In-vitro evaluation and comparison of the anti-microbial potency of commercially available oral hygiene products against Streptococcus mutans

Sentila R, Gandhimathi A, Karthika S, Suryalakshmi R, Michael A. In-vitro evaluation and comparison of the anti-microbial potency of commercially available oral hygiene products against Streptococcus mutans. Indian J Med Sci 2011;65:250-9     

Background: Dental caries is the destruction of enamel, dentin, or cementum of teeth due to bacterial activities, which if left untreated can cause considerable pain, discomfort, and treatment costs are very high. Of the oral bacteria, Streptococcus mutans is considered to be causative agent of dental caries in humans.

Aim: This study aims at screening the antibacterial potential of available oral hygiene products against S. mutans, the primary etiological agent. 

Materials and Methods: A selective number of toothpaste and mouth rinse available in the nearby local market was subjected to the study. The experiments were designed in a way to determine which one of these products had the greatest anti-S.mutans activity. Antibiotic sensitivity tests against the pathogenic strains were also conducted. 

Results and Discussion: Pathogenic strains of S.mutans were isolated from clinical dental specimen and identified using MTCC standard strain No. 890. Of the 86.66% samples which showed positive for S.mutans growth, almost 96% conferred sensitivity to 0.08 mg/ml of penicillin. Among the toothpastes used, A showed the maximum inhibitory activity against S.mutans inhibiting its growth even at a very low concentration of 0.0156 g/ml. Similar results were seen in the case of the mouth rinses used for the study, which showed that N had the most effective activity against S.mutans even at 1:8 dilution.  

Conclusion: The oral hygiene products containing triclosan proved to be the most effective followed by those containing fluoride. Herbal products showed comparatively lesser activity in inhibiting the growth of S. mutans. Even though there are so many products available to curb the progression of dental caries in the population targeted, there is still an undoubted prevalence and incidence of caries among the general public. The need for a better alternative to help control dental caries is on the rise even today.

Thursday, February 14, 2013

Tooth loss and periodontitis by socio-economic status and inflammation in a longitudinal population-based study.

J Clin Periodontol. 2013 Mar;40(3):203-11. doi: 10.1111/jcpe.12056.
Unit of Periodontology, Centre of Oral Health, University of Greifswald, Greifswald, Germany.



To examine the associations between factors of socio-economic status (SES), systemic inflammation and the progression of periodontitis and incidence of tooth loss.


Data of 2566 participants from the Study of Health in Pomerania (SHIP) with a 5-year follow-up were analysed. We evaluated attachment loss and tooth loss with regard to social variables including education, income, marital status and related risks such as smoking and obesity.


Socio-economic factors were associated with the progression of attachment level and tooth loss during the follow-up period. Low education and low income were associated with tooth loss (incidence risk ratio IRR 1.63, p < 0.001 and 1.25, p < 0.001 respectively) and also progression of mean clinical attachment level (p < 0.010 and p = 0.046 respectively). SES as well as smoking and obesity were also associated with increased levels of C-reactive protein (CRP) with effect modifications between SES factors and CRP, also between gender and marital status. Tooth loss was associated with disadvantageous SES, particularly under conditions of high CRP levels (p < 0.001).


The progression of periodontal disease is influenced by socio-economic factors. Effect modifications of socio-behavioural factors by CRP indicate that under conditions of systemic inflammation adverse SES effects may be aggravated.

Wednesday, February 13, 2013

Possible Link Between Obesity And Gum Disease

09 Feb 2013  

Impacting approximately one-third of the U.S. population, obesity is a significant health concern for Americans. It's a risk factor for developing type 2 diabetes, heart disease, and certain forms of cancer, and now, according to an article published in the January/February 2013 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General Dentistry (AGD), it also may be a risk factor for gum disease.

"We know that being overweight can affect many aspects of a person's health," says Charlene Krejci, DDS, MSD, lead author of the article. "Now researchers suspect a link exists between obesity and gum disease. Obese individuals' bodies relentlessly produce cytokines, proteins with inflammatory properties. These cytokines may directly injure the gum tissues or reduce blood flow to the gum tissues, thus promoting the development of gum disease."

Half of the U.S. population age 30 and older is affected by gum disease - a chronic inflammatory infection that impacts the surrounding and supporting structures of the teeth. Gum disease itself produces its own set of cytokines, which further increases the level of these inflammatory proteins in the body's bloodstream, helping to set off a chain reaction of other inflammatory diseases throughout the body.

Research on the relationship between obesity and gum disease is still ongoing.

"Whether one condition is a risk factor for another or whether one disease directly causes another has yet to be discovered," says AGD Spokesperson Samer G. Shamoon, DDS, MAGD. "What we do know is that it's important to visit a dentist at least twice a year so he or she can evaluate your risks for developing gum disease and offer preventive strategies."

The best way to minimize the risk of developing gum disease is to remove plaque through daily brushing, flossing, rinsing, and professional cleanings.

"A dentist can design a personalized program of home oral care to meet each patient's specific needs," says Dr. Shamoon.

Academy of General Dentistry. "Possible Link Between Obesity And Gum Disease." Medical News Today. MediLexicon, Intl., 9 Feb. 2013. 

Tuesday, February 12, 2013

Time to rinse! AI assistant helps clean your teeth

For most of us, brushing our teeth is just a tedious part of the daily grind. But for people with dementia or learning difficulties, such tasks can be difficult. They could soon gain more independence thanks to an AI designed by Christian Peters at Bielefeld University in Germany and his colleagues.
Peters has already come up with a system that guides people when washing their hands. Brushing teeth is more complicated because it involves many steps - such as putting toothpaste on the brush, filling a glass with water or rinsing the mouth.
The TEBRA system uses a video camera to monitor someone brushing their teeth and checks that each step happens at the right time. It prompts them via a screen on the washstand if they forget a step or if they get stuck. The idea is not to dictate a routine, but to adapt to that of the user, says Peters.
TEBRA is being tested at a care home in Bielefeld for people with learning disabilities. Caregivers there reported that the system was less distracting for some people than a human carer. The work will be presented at the International Conference on Health Informatics in Barcelona, Spain, next week. Peters also plans to adapt his system to tasks such as shaving.

Monday, February 11, 2013

What Are Perfect Teeth?

Having a couple wayward misaligned teeth is a trend in Japan, where cosmetic dentists are making that dream come true. Reminding us that beauty is everything and nothing.
Last spring, the world's first "snaggletooth girl group" gave their debut concert. They weren't called that by some execrable critic; the women's teeth are actually their sell. The title of their album is Mind If I Bite? 

The Tokyo-based group is called TYB48, and their Lou Pearlman-esque founder, Taro Masuoka, is actually a dentist in an upscale part of Tokyo. Masuoka runs a practice called Pure Cure, where they perform a lucrative cosmetic procedure called tsuke-yaeba that purposely gives people crooked teeth. So it works out nicely that he's also promoting the look in pop culture.
Before tsuke-yaeba (left) and after tsuke-yaeba (right). 
Via google translator: "example of your worries resolved"

As Japan Today put it, yaeba means "'multilayered' or 'double' tooth, and describes the fanged look achieved when molars crowd the canines and push them forward." They report it as a uniquely feminine trend: "Japanese women of all ages [are] flocking to dental clinics to have temporary or permanent artificial canines ... glued to their teeth." It's been gaining in popularity over the past few years.
Masuoka's dental practice made a commercial to sell the experience. (Heads up, the pace makes it almost unwatchable. It really starts to test you at the 2:10 mark when they spend 20 full seconds reclining her dental chair. And then zero seconds showing what they actually do to her teeth.)

Read the rest of the article

Saturday, February 09, 2013

In Vitro Comparison of Mechanical Properties and Degree of Cure of Bulk-Fill Composites

Journal of Esthetic and Restorative Dentistry

Volume 25, Issue 1, pages 72–76, February 2013

P. Czasch, N. Ilie Clinical Oral Investigations [Epub ahead of print]

To compare mechanical properties and degree of conversion of two bulk-fill flowable composite resins (Venus Bulk Fill, Heraeus Kulzer; SureFil SDR Flow, Dentsply Caulk, Milford, DE, USA).
Materials and Methods
The degree of conversion, Vickers hardness, and indentation modulus of Venus Bulk Fill and SureFil SDR Flow (SDR) were measured as a function of depth and polymerization time. Flexural strength and modulus of elasticity also were evaluated. The degree of conversion of the composite resins was evaluated at 0.1-, 2-, 4-, and 6-mm (the latter in bulk or in 2-mm increments) depths when light-activated for 10, 20, or 40 seconds using an Elipar Freelight 2 (3M ESPE) light emitting (LED) curing device. The 6-mm bulk-filled specimens were used for determination of hardness and indentation modulus. Flexural strength and modulus of elasticity were determined in a three-point bending test. The size of the fillers in each composite resin was assessed with field emission scanning electron microscope (FE-SEM).
Increased polymerization time increased the degree of conversion of 4- and 6-mm bulk increments for both composite resins. However, no improvement was noticed when the 6-mm bulk increments were polymerized for at least 20 seconds for Venus Bulk Fill and 40 seconds for SDR, compared to incrementally polymerized increments. When composite resins were compared, Venus Bulk Fill outperformed SDR, having a degree of conversion of approximately 5% higher for all irradiation times and depths. The most significant finding regarding hardness was that both composite resins reached a hardness value of 80% of the surface hardness at the depth of 6 mm. SDR had higher values for hardness and indentation modulus, and higher macromechanical properties values (flexural strength and modulus of elasticity) than Venus Bulk Fill. FE-SEM images showed SDR to have smaller particle fillers than Venus Bulk Fill.
SDR had better mechanical properties despite a lower degree of conversion than Venus Bulk Fill. Also, polymerization time of 20 seconds for 4-mm bulk placed increments of either material seems appropriate.
Results of this study revealed better properties for SDR than for Venus Bulk Fill. That was true despite its lower degree of conversion. It is worth noting that the study was performed in a laboratory setting with the light-curing unit very close to the material. That is unlikely to occur clinically, which may result in different properties and degree of conversion. According to the results of the present study, recommended irradiation times should suffice in providing adequate properties to the materials tested. Relevant properties are not compromised if the bulk-fill flowable composite resins are light-activated for at least 20 seconds when used in 4-mm increments.

Friday, February 08, 2013

Development of labial gingival recessions in orthodontically treated patients

American Journal of Orthodontics & Dentofacial Orthopedics
Volume 143, Issue 2 , Pages 206-212, February 2013


Our aim was to assess the prevalence of gingival recessions in patients before, immediately after, and 2 and 5 years after orthodontic treatment.


Labial gingival recessions in all teeth were scored (yes or no) by 2 raters on initial, end-of-treatment, and posttreatment (2 and 5 years) plaster models of 302 orthodontic patients (38.7% male; 61.3% female) selected from a posttreatment archive. Their mean ages were 13.6 years (SD, 3.6; range, 9.5-32.7 years) at the initial assessment, 16.2 years (SD, 3.5; range, 11.7-35.1 years) at the end of treatment, 18.6 years (SD, 3.6; range, 13.7-37.2 years) at 2 years posttreatment, and 21.6 (SD, 3.5; range, 16.6-40.2 years) at 5 years posttreatment. A recession was noted (scored “yes”) if the labial cementoenamel junction was exposed. All patients had a fixed retainer bonded to either the mandibular canines only (type I) or all 6 mandibular front teeth (type II).


There was a continuous increase in gingival recessions after treatment from 7% at end of treatment to 20% at 2 years posttreatment and to 38% at 5 years posttreatment. Patients less than 16 years of age at the end of treatment were less likely to develop recessions than patients more than 16 years at the end of treatment (P = 0.013). The prevalence of recessions was not associated with sex (P = 0.462) or extraction treatment (P = 0.32). The type of fixed retainer did not influence the development of recessions in the mandibular front region (P = 0.231).


The prevalence of gingival recessions steadily increases after orthodontic treatment. The recessions are more prevalent in older than in younger patients. No variable, except for age at the end of treatment, seems to be associated with the development of gingival recessions.

Thursday, February 07, 2013

Reduction in bacterial counts in infected root canals after rotary or hand nickel–titanium instrumentation – a clinical study

Rôças IN, Lima KC, Siqueira Jr JF. Reduction in bacterial counts in infected root canals after rotary or hand nickel–titanium instrumentation - a clinical study. International Endodontic Journal International Endodontic Journal, 00, 000000, 2013.



To compare the antibacterial efficacy of two instrumentation techniques, one using hand nickel–titanium (NiTi) instruments and the other using rotary NiTi instruments, in root canals of teeth with apical periodontitis.


Root canals from single-rooted teeth were instrumented using either hand NiTi instruments in the alternated rotation motion technique or rotary BioRaCe instruments. The irrigant used in both groups was 2.5% NaOCl. DNA extracts from samples taken before and after instrumentation were subjected to quantitative analysis by real-time polymerase chain reaction (qPCR). Qualitative analysis was also performed using presence/absence data from culture and qPCR assays.


Bacteria were detected in all S1 samples by both methods. In culture analysis, 45% and 35% of the canals were still positive for bacterial presence after hand and rotary NiTi instrumentation, respectively (> 0.05). Rotary NiTi instrumentation resulted in significantly fewer qPCR-positive cases (60%) than hand NiTi instrumentation (95%) (= 0.01). Intergroup comparison of quantitative data showed no significant difference between the two techniques.


There was no significant difference in bacterial reduction in infected canals after instrumentation using hand or rotary NiTi instruments. In terms of incidence of positive results for bacteria, culture also showed no significant differences between the groups, but the rotary NiTi instrumentation resulted in more negative results in the more sensitive qPCR analysis.

Wednesday, February 06, 2013

Glidewell Laboratories Launches BruxZir™ Shaded Milling Blanks

New Pre-Shaded BruxZir Milling Blanks from Glidewell Dental Lab Provide Improved Shade Consistency, While Increasing Efficiency and Lowering Costs in the Manufacture of BruxZir Solid Zirconia Restorations 

Newport Beach, CA (PRWEB) January 10, 2013
Glidewell Laboratories, industry-leading provider of dental laboratory products and services, announced today the release of BruxZir™ Shaded Milling Blanks for the milling of authentic BruxZir Solid Zirconia crowns & bridges. These pre-shaded milling blanks feature homogenous shading throughout the entire zirconia blank, providing dental labs with improved shade consistency, while saving them time and money.
Dental laboratories will now be able to produce BruxZir crowns & bridges with increased efficiency and lowered costs because they will no longer have to invest in coloring liquids or the labor required for the coloring process. BruxZir restorations milled from these pre-shaded blocks just need to be sintered before being finished using simple staining and glazing techniques. Compared to zirconia restorations that have been colored using the dipping technique, the BruxZir Shaded Milling Blank formulation provides total color penetration throughout the entire milling block, eliminating the possibility of white "show-through" after adjustment.
According to Robin Carden, vice president of research and development at Glidewell, the new BruxZir Shaded material also shows an increase in translucency. "Our team of chemists have worked very hard on this innovation," says Carden, "and have added a group of shading agents that work well with our patent-pending colloidal process. These proprietary shading agents do not leave any organic binders, such as carbon impurities, in the grain boundaries, so we are left with a very clean material that transmits the warm colors of the mouth through the BruxZir zirconia better than the dipped variety." Carden explains that when a full-contour zirconia restoration achieves translucency in the high color wavelength range (500-850 nanometers), or what is called the "warm color region," it makes a disappearing act in the mouth.
BruxZir Shaded Milling Blanks come in four base shades (100, 200, 300, 400) that can be stained to provide a lifelike match to all 16 shades in Vident’s VITA Classical Shade Guide range. Blank 100 provides base shades for A1, B1 and C1 VITA Classical shades; blank 200 provides base shades for A2, A3 and B2 VITA Classical shades; blank 300 provides base shades for A3.5, B3, C2, D2, D3 and D4 shades; and blank 400 provides base shades for A4, B4, C3 and C4 VITA Classical shades. Nearly 50 percent of all BruxZir restorations produced at Glidewell are made from the blank 200 shade group.
Like the original BruxZir Milling Blanks, BruxZir Shaded Milling Blanks are 98 mm in diameter and are available in 12 mm, 15 mm, 20 mm and 25 mm thicknesses. They can be used in many popular milling systems, including Glidewell’s BruxZir™ Milling System and milling units from Intelitek, Haas, VHF, Wieland Dental, Röders, Digital Dental Lab, imes-icore and B&D Dental Technologies.
For BruxZir Shaded Milling Blank pricing, more information or to place an order, call Glidewell Direct at 888-303-3975. To learn more about the BruxZir Authorized Lab program, visit
Glidewell Laboratories is a privately owned corporation that has more than 42 years of history as a provider of high-quality services and products to dental laboratories nationwide. It has its own R&D and manufacturing teams comprising 161 experienced professionals focused on Inclusive Dental Implant Solutions and BruxZir Solid Zirconia and is one of the most resourceful dental laboratories in the world. Its newly developed CAD/CAM processing capabilities are recognized as among the most advanced in the industry. To view our large selection of products and services, visit the Glidewell Laboratories website,

Tuesday, February 05, 2013

Ridge dimensional changes following single-tooth extraction in the aesthetic zone

Farmer M, Darby I. Ridge dimensional changes following single-tooth extraction in the aesthetic zone. Clin. Oral Impl. Res. 00, 2012; 16.



The aims of this study were to investigate the magnitude of the dimensional changes following extraction of a single tooth in the aesthetic zone over a 6- to 8-week healing period and to examine the degree and pattern of resorption of the buccal bone plate during this time frame.

Materials and methods

Twenty subjects who were to have a single tooth in the aesthetic zone extracted and replaced by an implant after a 6–8 week healing period were selected for this study. Hard and soft tissue measurements of the extraction site were obtained pre-extraction and were repeated 6–8 weeks post-extraction at defined points using a key.


After a 6- to 8-week healing period, the total ridge thickness in the crestal midline reduced by 15% of the original value. The buccal plate resorbed in an “inverted V shape”. Forty-two percentage of subjects had lost 4 mm or more of buccal bone in the midpoint of the extraction socket.


After a 6- to 8-week healing period post-extraction, there were significant reductions in the hard and soft tissue dimensions of the ridge, most notably on the most coronal mid-buccal aspect. All implants placed required simultaneous augmentation as a result.

Monday, February 04, 2013

Combined Osteotome-Induced Ridge Expansion and Guided Bone Regeneration Simultaneous with Implant Placement: A Biometric Study

Kolerman, R., Nissan, J. and Tal, H. (2013), Combined Osteotome-Induced Ridge Expansion and Guided Bone Regeneration Simultaneous with Implant Placement: A Biometric Study. Clinical Implant Dentistry and Related Research. doi: 10.1111/cid.12041



To evaluate the long-term outcome of a single-step ridge expansion osteotome procedure and implant placement combined with guided bone regeneration in patients presenting narrow maxillary alveolar ridges.

Materials and Methods

During the period 1999 to 2010, 41 patients aged 19 to 77 years (18 males; 23 females) suffering from partial or full edentulism associated with horizontal resorption of the maxillary ridges (2.5–5 mm) were treated using the combined ridge expansion and guided bone-regeneration techniques to obtain an improved bony base for implant placement. Implant survival, bone width measurements, clinical and radiologic implant success, and clinical complications were recorded and analyzed.


Achievement of primary stability of the implant was impossible at six sites; these were recorded as failures. In the remaining 35 patients, one hundred sixteen endosseous titanium implants were simultaneously placed. Follow-up time varied between 6 and 144 months (mean 52.4); of these, 36% were followed up for periods of time longer than 60 months. Implant diameter and lengths varied between 3.3 to 4.8 and 12 to 16 mm, respectively. In the 35 successful procedures (one hundred sixteen implants), the overall implant survival rate was 100%. An average gain in ridge width was 3.5 ± 0.93 (p < .0001) and an average enlargement of the buccal bone was 1.91 ± 0.6 (p  < .0001). The mean vertical mesial bone loss was 1.81 mm ± 1.07 (ranging from 0.3 to 4.2 mm), and the mean vertical distal bone loss was 1.74 mm ± 1.12 (ranging from 0.4 to 4.5 mm). In eight patients (32%), at least one implant presented bone loss of ≥3 mm.


Within the limitations of this study, we suggest that the combined osteotome-induced ridge expansion and guided bone regeneration simultaneous with implant placement is a reliable procedure with reduced morbidity and may offer an alternative in suitable situations.

Saturday, February 02, 2013

Novel calcium phosphate nanocomposite with caries-inhibition in a human in situ model

Dental Materials
Volume 29, Issue 2 , Pages 231-240, February 2013



Secondary caries at the restoration margins remains the main reason for failure. Although calcium phosphate (CaP) composites are promising for caries inhibition, there has been no report of CaP composite to inhibit caries in situ. The objectives of this study were to investigate the caries-inhibition effect of nanocomposite containing nanoparticles of amorphous calcium phosphate (NACP) in a human in situ model for the first time, and to determine colony-forming units (CFU) and Ca and P ion concentrations of biofilms on the composite restorations.


NACP with a mean particle size of 116nm were synthesized via a spray-drying technique. Two composites were fabricated: NACP nanocomposite, and control composite filled with glass particles. Twenty-five volunteers wore palatal devices containing bovine enamel slabs with cavities restored with NACP or control composite. After 14 days, the adherent biofilms were collected for analyses. Transverse microradiography determined the enamel mineral profiles at the margins, and the enamel mineral loss ΔZ was measured.


NACP nanocomposite released Ca and P ions and the release significantly increased at cariogenic low pH (p<0.05). Biofilms on NACP nanocomposite contained higher Ca (p=0.007) and P ions (p=0.005) than those of control (n=25). There was no significant difference in biofilm CFU between the two composites (p>0.1). Microradiographs showed typical subsurface lesions in enamel next to control composite, but much less lesion around NACP nanocomposite. Enamel mineral loss ΔZ (mean±sd; n=25) around NACP nanocomposite was 13.8±9.3μm, much less than 33.5±19.0μm of the control (p=0.001).


Novel NACP nanocomposite substantially reduced caries formation in a human in situ model for the first time. Enamel mineral loss at the margins around NACP nanocomposite was less than half of the mineral loss around control composite. Therefore, the Ca and P ion-releasing NACP nanocomposite is promising for caries-inhibiting restorations.

Friday, February 01, 2013

3M™ ESPE™ Filtek™ Supreme Ultra Universal Restorative Celebrates Successful “Changing Lives” Charitable Campaign

              More lives to be changed with generous donation of dental composite

ST. PAUL, Minn. – January 23, 2013 – For 10 years, dentists have been providing patients with esthetic and long-lasting restorations using the 3M™ ESPE™ Filtek™ Supreme Universal line of dental composite, adding up to more than 400 million restorations placed using the material. This past year, 3M ESPE honored that record with its “Changing Lives” campaign, in which the company donated one unit of Filtek Supreme Ultra universal dental composite to a dental charity for every four-unit order purchased by a dentist.

Based on the success of the Changing Lives campaign, 3M ESPE donated $40,000 worth of dental composite to Give Kids a Smile – St. Louis, the National Children’s Oral Health Foundation: America’s ToothFairy, and Oral Health America. With these dental composite donations, the charities are restoring more smiles.

The Changing Lives campaign continues to celebrate stories and testimonials shared by dentists of how Filtek Supreme Ultra dental composite helped them make a difference in the lives of their patients. First introduced in 2002, the Filtek Supreme line of dental composite has come to be prized in practices around the world for its true nanotechnology, which enables dentists to use the dental composite to easily create restorations from the front to the back of the mouth. Over the past decade, the Filtek Supreme line has been the market-leading nanocomposite in the U.S., favored for its exceptional handling, lasting polish and superior wear. The dental composite makes it easy for dentists to change patients’ lives with beautiful lifelike results.

For more information, visit 


3M ESPE is a dental product manufacturer that markets more than 2,000 dental products and services. 3M ESPE dental products are designed to help dental professionals improve their patients' oral health care. 3M Health Care, one of 3M’s six major business segments, provides world-class innovative products and services to help health care professionals improve the practice and delivery of patient care in medical, oral care, drug delivery and health information markets. For more information on the complete 3M ESPE line of dental products, visit the 3M ESPE website at or call the 3M ESPE Technical Hotline at 1-800-634-2249. Products are available for purchase through authorized 3M ESPE distributors.

3M, ESPE and Filtek are trademarks of 3M or 3M Deutschland GmbH.  Used under license in Canada. © 3M 2013.  All rights reserved.

About 3M

3M captures the spark of new ideas and transforms them into thousands of ingenious products. Our culture of creative collaboration inspires a never-ending stream of powerful technologies that make life better. 3M is the innovation company that never stops inventing. With $30 billion in sales, 3M employs 84,000 people worldwide and has operations in more than 65 countries. For more information, visit or follow @3MNews on Twitter.